Type 2 Diabetes Mellitus and Eradication in a Clinical Population.

OBJECTIVES

Eradication of reduces the risk of gastric cancer (GC). Individuals with type 2 diabetes mellitus (T2DM) are known to be at increased risk for GC. In a cohort of -positive individuals, we assessed whether those with T2DM were at risk of persistent infection following treatment compared with individuals without T2DM.

METHODS

A random subset of all individuals diagnosed as having without intestinal metaplasia at endoscopy from 2015 to 2019 were stratified evenly by race (Black and White). After excluding those with T1DM and those without eradication testing after treatment, logistic regression analysis was used to determine the association of T2DM with the risk of persistent infection following treatment.

RESULTS

In 138 patients, eradication rates did not differ between the 27% of individuals with T2DM compared to those without (81.1% vs 81.2%). After adjusting for age, race, and insurance status, we found no significant increased risk of persistent infection for individuals with T2DM (odds ratio 1.40; 95% confidence interval 0.49-3.99).

CONCLUSIONS

eradication rates do not differ by T2DM status, providing support for clinical trials of eradication to reduce GC incidence among high-risk populations in the United States, such as individuals with T2DM.